Lantheus Holdings is assessing a potential acquisition offer after receiving a takeover proposal from Curium Pharma that values Lantheus at about $7 billion, according to people familiar with the matter. The companies have been engaged in talks that could lead to a transaction within weeks, although no final decision has been reached and there is no certainty the discussions will conclude in a deal.
The bid would place Lantheus in the orbit of a private-equity backed buyer whose own valuation was approximately $7 billion last year. That valuation followed fundraising by CapVest Partners for a continuation vehicle associated with Curium, the nuclear medicine company that would be the acquirer in this reported approach.
Neither party has confirmed a transaction. Requests for comment from the companies did not receive immediate responses, and persons briefed on the situation have framed the matter as active discussions rather than a concluded agreement.
Market reaction has been muted. Lantheus, a company focused on radiopharmaceuticals, saw its shares trade down nearly 2% in extended trading following the report. The stock has nonetheless delivered strong performance earlier in the year, rising 54.8% year-to-date and carrying a market capitalization of about $6.15 billion.
The current state of negotiations appears fluid: participants are talking, there is a potential valuation in the neighborhood of $7 billion on the table, and observers indicate a timeline measured in weeks for possible developments. That same commentary stresses the absence of any definitive decision and cautions that an agreement is not assured.
For investors and market participants, the situation presents a live M&A story with several moving parts: the buyer's prior valuation activity tied to a continuation vehicle, the ongoing negotiations between the two companies, and the immediate market response reflected in share price movement and market capitalization. How the discussions unfold will determine whether the reported approach culminates in a transaction or stalls without a sale.